ArticleCureus2026
Gliosarcoma: A Case Series and Comprehensive Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliosarcoma represents an uncommon primary neoplasm of the central nervous system, distinguished by a biphasic histological architecture that combines glial and mesenchymal elements. In this report, we present three cases of intracranial tumors confirmed histopathologically as gliosarcoma, offering a comprehensive account of their clinical presentation, neuroimaging characteristics, and pathological features. The lesions involved different cerebral regions, specifically the frontal, temporal, and occipital lobes, and manifested with a heterogeneous range of symptoms, including headache, focal motor weakness, and epileptic seizures. The series comprises two male patients and one female patient, aged 54, 51, and 63 years. All patients underwent surgical resection, followed by adjuvant radiotherapy with concurrent and/or adjuvant temozolomide. Despite multimodal treatment, disease progression occurred, consistent with the aggressive biological behavior of gliosarcoma, which is associated with a reported median overall survival of approximately 13-16 months. Through detailed analysis of each case, we highlight the key clinical, radiological, and histopathological findings, emphasizing their diagnostic value and the importance of integrating treatment and outcome data to contextualize prognosis in this rare tumor entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.